We are live on ! Find out more
CALA

Calithera Biosciences, Inc
CALA

Delisted

CALA was delisted on the 1st of February, 2023.

Back to rankings

22 hedge funds and large institutions have $5.02M invested in Calithera Biosciences, Inc in 2022 Q3 according to their latest regulatory filings, with 2 funds opening new positions, 4 increasing their positions, 9 reducing their positions, and 7 closing their positions.

New
Increased
Maintained
Reduced
Closed

13% more capital invested

Capital invested by funds: $4.44M → $5.02M (+$586K)

21% less funds holding

Funds holding: 28 → 22 (-6)

56% less repeat investments, than reductions

Existing positions increased: 4 | Existing positions reduced: 9

71% less first-time investments, than exits

New positions opened: 2 | Existing positions closed: 7

Holders
22
Holders Change
-6
Holders Change %
-21.43%
% of All Funds
0.38%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
2
Increased
4
Reduced
9
Closed
7
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Vanguard Group
Vanguard Group
Pennsylvania
+$91.6K
2
JP Morgan Chase
JP Morgan Chase
New York
+$48.8K
3
Renaissance Technologies
Renaissance Technologies
New York
+$47.4K
4
BNP Paribas Financial Markets
BNP Paribas Financial Markets
France
+$4.12K
5
AIM
Axiom Investment Management
New York
+$855

Top Sellers

Rank Fund Capital Flow
1
Alyeska Investment Group
Alyeska Investment Group
Illinois
-$123K
2
Two Sigma Investments
Two Sigma Investments
New York
-$49K
3
TRCT
Tower Research Capital (TRC)
New York
-$40.5K
4
Citadel Advisors
Citadel Advisors
Florida
-$40.3K
5
VF
Virtu Financial
New York
-$38K
Name Holding Trade Value Shares
Change 		Change in
Stake
BI
1
BVF Inc
California
$1.37M – – –
Primecap Management
2
Primecap Management
California
$1.22M -$19.8K -5,800 -1%
Citadel Advisors
3
Citadel Advisors
Florida
$587K -$40.3K -11,794 -6%
Acadian Asset Management
4
Acadian Asset Management
Massachusetts
$455K – – –
Vanguard Group
5
Vanguard Group
Pennsylvania
$415K +$91.6K +26,800 +23%
Renaissance Technologies
6
Renaissance Technologies
New York
$337K +$47.4K +13,855 +14%
BlackRock
7
BlackRock
New York
$246K -$32K -9,367 -10%
TCMG
8
TSP Capital Management Group
New Jersey
$185K – – –
Geode Capital Management
9
Geode Capital Management
Massachusetts
$85K – – –
JP Morgan Chase
10
JP Morgan Chase
New York
$59K +$48.8K +14,264 +245%
State Street
11
State Street
Massachusetts
$32K – – –
Wells Fargo
12
Wells Fargo
California
$14K -$3 -1 -0%
TRCT
13
Tower Research Capital (TRC)
New York
$8K -$40.5K -11,856 -82%
Group One Trading
14
Group One Trading
Illinois
$5K -$4.65K -1,361 -45%
BNP Paribas Financial Markets
15
BNP Paribas Financial Markets
France
$3.55K +$4.12K +1,206 New
FCA
16
FinTrust Capital Advisors
South Carolina
$3K – – –
Morgan Stanley
17
Morgan Stanley
New York
$2K – – –
Bank of America
18
Bank of America
North Carolina
$2K +$51 +15 +3%
UBS Group
19
UBS Group
Switzerland
$1K -$2.32K -679 -68%
Alyeska Investment Group
20
Alyeska Investment Group
Illinois
– -$123K -50,000 Closed
Two Sigma Investments
21
Two Sigma Investments
New York
– -$49K -19,947 Closed
VF
22
Virtu Financial
New York
– -$38K -15,456 Closed
D.E. Shaw & Co
23
D.E. Shaw & Co
New York
– -$28K -11,249 Closed
Susquehanna International Group
24
Susquehanna International Group
Pennsylvania
– -$25K -10,177 Closed
TFO
25
Tarbox Family Office
California
– -$25K -10,000 Closed
1
2

CALA Hedge Fund Activity: Q3 2022 in Review

22 of the 5,806 institutional investors tracked by Wall St. Rank reported a position in Calithera Biosciences, Inc (CALA) for Q3 2022, worth a combined $5.02M — up 13% from $4.44M a quarter earlier.

Sellers outnumbered buyers: 7 funds closed out of CALA and 2 opened new positions — a net loss of 5 holders — while 9 trimmed existing stakes and 4 added.

The largest buyer was Vanguard Group, adding an estimated $91.6K. The largest seller was Alyeska Investment Group, exiting entirely with an estimated $123K sold.

  • 22 institutional investors held Calithera Biosciences, Inc (CALA) as of Q3 2022, down from 28 in Q2 2022.
  • Funds reported $5.02M of Calithera Biosciences, Inc stock for Q3 2022, up 13% quarter-over-quarter.
  • 2 funds opened new Calithera Biosciences, Inc positions in Q3 2022 and 7 closed out, a net change of -5 holders.
  • The largest Calithera Biosciences, Inc buyer in Q3 2022 was Vanguard Group, an estimated $91.6K added.
  • The largest Calithera Biosciences, Inc seller in Q3 2022 was Alyeska Investment Group, an estimated $123K sold.

Based on aggregated 13F filings for Q3 2022.